Predictive and Diagnostic Value of Tau and Beta-amyloid Markers in the Dementia of Parkinson's Disease
Trial
Early Phase 1
Completed
Sept. 17, 2014
Post Marketing Surveillance Study in Patients With Idiopathic Parkinson's Disease
Trial
N/A
Completed
Sept. 16, 2014
Automated Parkinson's Disease (PD) Motor Symptom Assessment for Deep Brain Stimulation (DBS) Programming
Trial
N/A
Completed
Sept. 14, 2014
Observational Study in Parkinson's Disease of the Primary Care Population of Patients Treated With Pramipexole
Trial
N/A
Completed
Sept. 10, 2014
Ophthalmologic Safety of Long Term Treatment With Pramipexole Compared to Bromocriptine or Other Dopamine Agonists in Patients With Parkinson's Disease
Trial
Phase 4
Completed
Sept. 7, 2014
The Effect of Sifrol® on Tremor and Depression in Patients With Idiopathic Parkinson's Disease
Trial
N/A
Completed
Sept. 3, 2014
Safety, Tolerability and Efficacy of Switching From Talipexole to Pramipexole in Patients With Parkinson's Disease
Trial
Phase 4
Completed
Sept. 3, 2014
WiiMote Game Controller as a Device to Study Movement Disorders
Trial
N/A
Terminated
Aug. 31, 2014
State Dependent Resonance in the BG-cortical Loops
Trial
N/A
Completed
Aug. 27, 2014
Effectiveness Study of Occupational Therapy in Parkinson's Disease
Trial
N/A
Completed
Aug. 26, 2014
The Effect of Low-frequency rTMS on Motor Function in PD Patients With Freezing of Gait
Trial
N/A
Unknown
Aug. 19, 2014
Open Label Treatment With tDCS for Parkinson's and Related Disorders for Improvement of Speech, Gait and Mood
Trial
Phase 1
Completed
Aug. 19, 2014
Long-Term Dopamine Transporter Imaging and Clinical Assessment of Parkinson's Disease Progression
Trial
Phase 2
Completed
Aug. 7, 2014
Electrophysiological Investigation and rTMS Intervention of Ambulatory Central Processing of Freezing of Gait in Parkinson's Disease
Trial
N/A
Withdrawn
Aug. 7, 2014
Survey on PD Patients With Depressive Symptoms
Trial
N/A
Completed
Aug. 5, 2014
A 12-week Study of Pramipexole Extended Release (ER) in Patients With Parkinson's Disease (PD), Followed by a 52-week Long-term Treatment Period
Trial
Phase 2
Completed
July 30, 2014